Search
Streptococcus pneumoniae type 19a capsular polysaccharide antigen
go.drugbank.com/drugs/DB10337ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: SII PNEUMOSIL Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) (10-Valent) SUSPENSION FOR INJECTION (MULTIDOSE - 5 DOSE), PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADETLevopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnIt was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. … This drug presented different dosages and it was administered as a capsule or suspension.
MM-093
go.drugbank.com/drugs/DB05512InvestigationalCurrent studies are assessing MM-093’s potential to improve the treatment of autoimmune disease. … MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigational[L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … [A20298,A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 SubstratesSuprofen
go.drugbank.com/drugs/DB00870ApprovedWithdrawnIt inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsLixmabegagene relduparvovec
go.drugbank.com/drugs/DB16816InvestigationalLixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1).
Estetrol
go.drugbank.com/drugs/DB12235ApprovedInvestigationalEstetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world. … [L33179] In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.[L33209]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationallate-phase CINV during the first 120 hours post-chemotherapy. … Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsPrasterone
go.drugbank.com/drugs/DB01708ApprovedInvestigationalNutraceuticalIn November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause … DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements.
Synonyms: 3β-hydroxyandrost-5-en-17-one, 3-beta-hydroxy-5-androsten-17-oneCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTopiroxostat
go.drugbank.com/drugs/DB01685InvestigationalRenal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. … Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat.
Synonyms: 4-(5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrileCategories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors